

# INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

[ISSN: 0975-4725; CODEN(USA): IJPS00] Journal Homepage: https://www.ijpsjournal.com



#### **Review Article**

# **Artificial Intelligence in Pharmaceutical Production**

# Shruti Kapadne\*, Tejaswini Khairnar, Rutika Karad, Sakshi Kawale, Pankaj Aher

Loknete Dr. J D Pawar College of Pharmacy, Kalwan, Nashik, India.

#### ARTICLE INFO

Published: 04 Feb. 2025 Keywords: Artificial intelligence, Drug formulation, Drug Product Development, Machine Learning. DOI: 10.5281/zenodo.14802836

#### ABSTRACT

The process for developing new medications is expensive, time-consuming, and prone to errors. Artificial intelligence has demonstrated significant potential as a transformational tool in drug discovery in recent years, providing creative solutions to challenging problems faced by the pharmaceutical sector. The article covers the network and tool of artificial intelligence and how they are used in pharmaceutical development process, covering a range of topics such drug distribution, manufacturing, quality control, and clinical trial management. AI can do everything from working to improve accuracy and reduce error in work to opening up new ideas previously considered unthinkable. This is a technique that the pharmaceutical industry is using for the production of new drugs. It includes optimizing medication designs and predicting structures of molecules. AI also helps in repurposing drugs by rapidly and costeffectively identifying the available drugs for new medical applications. During the last couple of decades, there has been increased interest in applying machine learning techniques (MLT) as tools in drug creation. The reason for such interest is that designing drugs is an extremely complicated process that requires hybrid methodologies. A very brief overview of a few. MLT, which includes support vector machines, autonomous maps, multilayer perceptual neurons, Bayesian neural networks, and counterpropagation neural networks, is discussed in this paper. AI is multiskilled tool with a variety of algorithms that can be used in different situations. Tablet, capsule, powder granules, and other solid dosage forms are some of the most commonly utilized types of administration. The study concludes by outlining the possible applications of artificial intelligence in medication formulation and development, with a focus on rapid formulation optimization, precise drug targeting, and customized medicine. In this topic, the ethical ramifications of AI are also covered, including concerns about accountability, bias, and confidentiality.

#### **INTRODUCTION**

\*Corresponding Author: Shruti Kapadne

Address: Loknete Dr. J D Pawar College of Pharmacy, Kalwan, Nashik, India.

**Email** : shrutikapadne780@gmail.com

**Relevant conflicts of interest/financial disclosures**: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



Artificial intelligence can be defined as the capacity of technology-encoded algorithms to learn from data in order to carry out automated tasks without the need for human intervention at every stage. According to the WHO, AI has enormous potential for promoting universal health care and human welfare in the future. However, for society, health systems, and people to be able to effectively avail themselves of AI properly, risks and ethical issues related to the technology need to be resolved. This, in turn, has increased the demand for suitable guidelines, policies, and procedures to be developed and implemented, in direct proportion to the rapidity with which technology is advancing and is increasingly being used for all sorts of rather unexpected applications. <sup>[3]</sup> The pharmaceutical industry's use of AI in drug and vaccine research, clinical testing, and marketing is expanding. The growing usage of AI in development and implementation is briefly summarized in this discussion paper. Not all the concepts or challenges covered are addressed directly in the document, however: many apply to the increasingly expanding field of medical artificial intelligence, including the domain of diagnostic tools. WHO has set guidelines for validation, evaluation, and training for the use of [3] AI in cervical cancer screening. The past decade has seen an explosion in artificial intelligence and machine learning largely due to breakthrough technological advancement in computing technology. As a direct result, largescale data acquisition and processing capabilities have undergone revolutionary changes. However, the expenses of introducing new medications to the market and to patients has advanced. dramatically. The term "R&D" will be used throughout the report to refer to the science, research, and procedures associated with drug development-from drug discovery to clinical development and implementation to life-cycle management.<sup>[4]</sup>

Robotics artificial intelligence are are revolutionizing medicine and health care. AI enables healthcare providers to make better providing them decisions bv with more informative, tailored patient data. Patients and their families benefit from improved clinical outcomes as well as more effective treatments. Health delivery has become faster because of robotics and AI, but also more supercomputing accelerates drug discovery and design processes. <sup>[4]</sup> The intelligence of humans is being simulated by a computer. It involves data collection, providing the rules for the use of data, drawing tentative or conclusive conclusions about the information received, and self-error correction. AI development is viewed as a two-edged sword; more people are worried that it may cut off their jobs, but every new advance is celebrated because of its enormous potential to improve society. AI has been greatly utilized, ranging from automating commercial procedures to state-of-the-art teaching strategies. Starting from hype to hope, change has come into the emerging concept on using AI in the design of new drugs. The article provides information on the effectiveness and mortality of scientific pharmaceutical research and development, the possible AI's utilization in medication manufacturing pipeline phases within drug development plans and processes, and collaborations between AI and pharmaceutical companies.<sup>[10]</sup>

# 2. Machine Learning and Artificial Intelligence In The Pharmaceutical Sector

The study of software techniques that enable computers to automatically learn from experience and improve at it is known as machine learning. It is typically considered a part of artificial intelligence. In order for the systems to learn from and enhance learning by machine algorithms must be applied. Making conclusions is made easier by machine learning algorithms.<sup>[5]</sup>





### 2.1 Types of Machine Learning

Three primary categories of machine learning can be distinguished. These are the ones.

#### 2.1.1 Supervised Learning

When the data includes both output goal values and input variables, supervised learning is employed. An algorithm transforms an input function into an output function. The goals are to identify the risk generator and to pursue optimization of clinical trials.<sup>[5]</sup>

### 2.1.2 Unsupervised Learning

This is the reverse of learning under supervision. This suggests that informal learning is carried out when the data is only accessible as an input and there is no correlating output variable. Grouping is one of the most commonly utilized types of unsupervised algorithms. This method predicts the outcome for undetermined inputs by using the intrinsic groups present in the data. Predicting consumer buying patterns is one application of this strategy.<sup>[5]</sup>

### 2.1.3 Reinforcement Learning

The process of unsupervised learning is comparable to it. The task is to generate a judgment order using the machine learning method. A machine is placed in an environment that resembles a game in some ways. <sup>[5]</sup>

### Example

### 1. teaching agents how to play games

2. Completing robotic tasks with a predetermined outcome. <sup>[5]</sup>



Fig.2: Types of machine learning

Learning in

# 3. Application of MachinePharmaceutical Sector.3.1 Disease Identification:

Machine learning research in the medical field basically revolves around the diagnosis and detection of disorders. Cancer is still one of the main medical problems under extensive attention. The medication and treatment processes of cancer have been found to require vast amounts of medications and treatments.<sup>[5]</sup>

#### **3.2 Improved Medical Outcomes:**

This does not mean machine learning can replace doctors, but while it cannot, it will still be of assistance in medical care. Doctors have a treasure trove of information; however, it may find trouble in the proper interpretation and successful application of the data. <sup>[5]</sup>

### 3.3 Personalized Care:

This can be applied to provide very effective personalized treatment using health data. The

expectations from the growing number of microdevices and biosensors include better assessment of health, and remote monitoring increases the efficacy of treatment. <sup>[5]</sup>

#### 3.4 Evaluation of Drug Effectiveness

The complexity of the genome, proteomics, and metabolomics data makes expert bio-diagnostics hard to define. While aspects of biology are used in machine learning, patient data remains scarce for basically accurate information. The confluence of the novelness of data mining with the adaptability of machine learning provides new insights. <sup>[5]</sup>

#### **3.5 Improved Patient Care:**

While machine learning has made it easy to handle large data from huge numbers of patients, it can become problematic for physicians to deal with such cumbersome patient data. In an attempt to reduce the workload and efforts of doctors, many machine learning systems are available.<sup>[5]</sup>

4.Application Of Artificial Intelligence In Pharma Sector





# 4.1 Artificial Intelligence in Pharma Industry

Since AI and machine learning have such wideranging applications-as this article explores, there is such an enormous benefit of applying them in the pharmaceutical industry. Nearly all of the medicament research process's steps can benefit from the Utilization of machine learning, or AI. from laboratory evidence of perception to final product analysis and promotion. <sup>[13]</sup>Artificial Intelligence can make a substantial investment in accelerating and scaling the drug discovery process that has taken an average of \$2.6 billion and ten years. There is unprecedented growth in the number of startups and pharmaceutical businesses that are now using AI in developing medications over the past ten years. Many of the pharmaceutical companies, such as Novartis and Pfizer with IBM Watson, have either collaborated or acquired AI technologies. Mak and Pichika (2019) convey an adequate list. of pharmaceutical and AI firms as well as the pertinent areas of cooperation in developing drugs, such as transforming medicines, customized medication and the development of new drugs. In the areas of targeted marketing, robotic production, and automation of processes. pharmaceutical



companies also been researching AI applications. [13]

# **4.2** Application of Artificial Intelligence in Drug Discovery

Drug innovation is the process of identifying and producing novel medications for the market. The multi-step procedure takes about 15 years on average to complete. Quickly phase of Investigation of drugs, a decision is made on which illness to approach and what target one might make a difference in the disease. Largescale screening tests are then used in exploratory research to assist in identifying the targeted HIT molecules, which are chemical molecules with a affinity promising for the target being investigated. More research is then conducted to

identify a chemical that selectively and specifically binds to the target but which has the capability of changing its typical mechanism of action. We call the molecule the LEAD compound. Thereafter, the lead was completely improved. to improve its ADME properties as well as biological activity. f a lead molecule is screened in, the drug enters both the preclinical phasesformulation research and animal experiments and the clinical phases. Until regulatory agencies- the FDA or EMA-have granted approval after clinical trial completion, the medicine cannot be marketed. When a drug reaches the market, the same science that developed the drug will now monitor its safety throughout distribution.<sup>[7]</sup>



Fig: 4: A schematic describing the main phases of the drug development and discovery process.

# 4.2.1 Identification and Verification of the Target

Actually, Artificial Intelligence has been very critical in identifying and validating potential therapeutic targets. Algorithms by AI find or identify genes or proteins associated with the disease pathways through the analysis of the biological data, for instance, the expression levels of genes and protein structures. Finally, validation could be done in vitro and in vivo by establishing its relevance to disease progression. AI-driven target discovery also aided in the search for new drug targets and design targeted therapeutics for several other diseases, which include cancer, cardiovascular problems, and neurological conditions.<sup>[7]</sup>

### 4.2.2 Molecular Design and Optimization

AI has revolutionized the design and optimization approach of molecules and allowed scientists to synthesize novel compounds, which may possess novel properties. Through deep learning algorithms, researchers are now able to make ideal chemical structures, which may effectively bind to any particular target; synthesized to evaluate their efficacy and safety afterward. Now, the task is not just possible but has also been done in much lesser time and expense by AI-driven molecular design to find prospective drugs with much greater speed and efficiency to investigate a much wider chemical space compared to traditional approaches used in drug discovery.<sup>[7]</sup>

# 4.2.3 Virtual Screening and Pharmacophore Modeling

Virtual screening is a computation-guided approach for surveying expansive libraries of chemicals for prospective therapeutic leads. By applying Artificial intelligence machine learning that can view chemical structures and predict what those structures would do in an interaction with target proteins, researchers can choose drugs for real experimentation. The AI-driven methodology referred to here as pharmacophore modeling identifies the key characteristics of a chemical that are necessary for it to bind to a target. Scientists design compounds of maximal binding affinity and specificity by pharmacophore modeling of a target protein. <sup>[7]</sup>

#### **4.3 Artificial Intelligence in Drug Formulation**

Other formulations, such as solid dispersions, extrusions, the Liposomes, micron-sized particles and granules, have been produced within the pharmaceutical field in addition to the conventional dosage forms. These are all referred to as "formulation techniques" since they make it possible to formulate or provide regularly used such dosage forms. tablets. additional functionality. AI usage in manufacturing strategies are especially valuable for research to develop future-oriented medication products with intended effectiveness and Health consequences. because they can effectively handle a wide range of An active ingredient obstacles, such as poor solubility, strength, their bioavailability and potential for manufacturing.<sup>[8]</sup>

#### **4.3.1 Controlled Release Tablet Formulation**

In the development of controlled-release formulation, scientists make use of ANN and pharmacokinetic simulations. Chem software enables the ANN model to learn difficult and dedicated skills from the data units for input and output. Using a complex artificial neural network model, the scientists forecast the ideal formulation of tablets on the basis of two ideal in vitro dissolving time profiles and two desirable in vivo release profiles. The rate-limiting phase in the drug's in vivo absorption is thought to be dissolution, as it is directly correlated to the amount of drug consumed. Both the similarity factor (F2) and the difference factor (F1) are frequently employed to identify potential patterns of in vitro release. <sup>[8]</sup>

### **4.3.2 Formulation of Rapid Release Tablets**

To increase strength of tablets, Turkoglu created a direct compressed tablet formulation with hydrochlorothiazide. In order to explain the characteristics of the granules and tablets (disintegration time, hardness, and friability), process variables (granulator type, binder addition technique), and the binder and dispersing agent proportions in Every preparation, Kesavan and Peck created a model of the formulation of caffeine tablets. These two analyses illustrated neural networks that have superseded conventional statistical methods. Hence, the results by Kesavan and Peck were subsequently reexamined by investigators who employed a variety of evolutionary algorithms and neural networks. This paper represented how the optimal formulation depended on the constraint enforced on the numerous levels of processing and elements variables and the relative emphasis of the output attributes. Data were analyzed based on neurofuzzy computing.<sup>[8]</sup>

# **4.3.3** Formulation of a Hard Gelatin Capsule Shell.

Formulations for hard gelatin capsules are developed utilizing regulatory techniques such as artificial neural networks (ANN) and systems of expertise (ES). Artificial neural networks (ANNs) promote human brain functions like learning,



generalization, prediction, and knowledge abstraction. With the support of artificial neural networks (ANNs), information and statistics acquired during research efforts may be quickly transformed into wisdom, enabling the manufacturer to predict the features of the theoretical preparation or create a few domainspecific plans for upcoming events. In 2005, Wendy I. Wilson developed a production of capsule shells process for Categorization System II for Pharmaceuticals medications, including Ibuprofen, naproxen, ketoprofen, and carbamazepine, by expanding the Expert Network and doing analysis. Despite the limitation of just offering a suggested composition, Capsugel's expert approach for the manufacture of hard gelatin capsules containing granules was utilized globally. The first test, the researchers said the system was highly erroneous and inaccurate in its prediction. Models with an R2 of under 70 percent were generated when the researchers re-trained the artificial neural networks using a different dataset. The smart hybrid system predicted that roughly 5% of the model medications would be soluble. Researchers demonstrated that the system could produce formulation that met its performance requirement by cross validating only 10% of the recently obtained data. Researchers demonstrated how the system may evaluate numerous BCS class II drugs, taking into account their intrinsic dissolving properties and wettability.<sup>[8]</sup>

### **4.3.4 Solid Dispersion Forms. (SD)**

A single or several distributed APIs within a Solidified matrix are referred to as solid dispersions. They are presently useful and affordable product way to increase solubility and bioavailability. They've been frequently applied to alleviate the poor solubility of APIs in both researchers and industry. In many AI-based SD studies, artificial neural networks (ANN have been used to optimize the formulations. To enhance the drug discharge and floating capabilities of PEG- based effervescent mixes containing Nimodipine SD, Investigators applied artificial neural networks (ANNs). The link involving temperature, PEG molar mass, and API concentration was explained using ANNs in a PVP-based SD. Using machine learning techniques, researchers have created a model to forecast SD stability. They used twenty molecular descriptors to compare eight ML for this purpose. <sup>[8]</sup>

# 4.3.5 Emulsions, Microemulsions, and Nanoemulsions

Emulsions are stabilized by an emulsifier. The oil and water phases are spread out over each other, making it a biphasic system. The use of micro- and nanoemulsions could yield numerous advantages, including improved shelf stability, superior optical clarity, and higher API permeability. Research on these systems based on the application of AI techniques was reported by various investigators. To stabilize the o/w emulsion, Kumar et al. used ANNs in adjusting the level of fatty alcohol. The following relative characteristics of the product of the emulsion were consistently predictable with the aid of ANNs: particle size, zeta potential, conductance, and viscosity. Additionally, they made it probably to quantify the relative relevance of raw materials. By developing two artificial neural networks (ANNs) that can identify the type of microemulsion based on either a differential scanning calorimetry (DSC) curve or the intended composition, Gasperlin et al. were able to correctly forecast the structures of microemulsions. Furthermore, utilizing ANN model data, To treat the continuing stage of tuberculosis, Agatonovic-Kustrin et al. established an ideal Formulation of microemulsions for the orally administered rifampicin and isoniazid. In their investigation of potential factors on nanoemulsion particle size, Amani et al. used artificial neural networks (ANNs) and discovered that the most important element influencing the final particle size Was the whole amount of energy used for preparation.



Seyed et al. also investigated the nanoemulsion's concentrations of the ingredients in an effort to identify the most stable structure with the least amount of cytotoxicity. They discovered that cytotoxicity was unaffected by emulsifier concentration, which was determined to be the main factor influencing Nanoemulsion stable state. <sup>[8]</sup>

# 4.3.6 Self-emulsifying Drug Delivery System (SEDDS)

SEDDS is formulated from a drug-oil-surfactant mixture, in the presence of cosolvent when needed, isotropically. Owing to physical stability, ease of preparation, and ability to solve the problem of poor drug bioavailability, several advantages have been associated with SEDDS. Based on the problems of APIs that SEDDS can effectively solve for, they include problems in bioavailability, gut wall efflux, enzymatic degradation, and solubilization. Fatouros et al. developed a Method of dynamic lipolysis replicating medication absorption and predicting the IVIVC by the use of artificial intelligence approaches such as neurofuzzy networks. It has been observed in the model that high predictability without involved parameters suggests that it might be applied to predict in-vivo behavior of lipid formulations. Parikh and Sawant used ANNs and I-optimal design to optimize the crucial parameters determining SEDDS size of droplets. The ANNcoupled replicas were able to define the percentage contribution of each factor with a higher accuracy than that of the quadratic model coupled with Ioptimal design. Li et al. also constructed QSPR models exploiting MLR and ANN methodologies. These models correlate the drug solubility with the molecular structure of the oil, drug, surfactant, and cosurfactant used in SEDDS. They concluded that the intensity of this dipole, the strength of the most highly occupancy molecule orbital, as well as oil and surfactant ratios, had a deep impact on drug solubility qualities.<sup>[8]</sup>

# 5. Artificial Intelligence In Drug Development5.1 Predicting Physiochemical Characteristics

The solubility and partition coefficient or degree of ionization, log P, and intrinsic permeability are all physicochemical qualities that must be considered while building a new medicine because they have an related influence on the medication's pharmacokinetics and specific target group. Many AI- based methods can be applied for the prediction of physicochemical properties. For instance, machine learning trains the algorithm on gigantic data sets it finds generated by compound optimization that was performed previously. Drug design techniques use molecular descriptors including SMILES strings, potential energy measurements, electron density surrounding the molecule, and 3D atoms coordinates to provide believable compounds using DNN and forecast their characteristics. Zang et al. developed the Estimation Program Interface (EPI) Suite, a structure-property quantitative connection procedure for detecting the six physiological features of EPA-sourced environmental chemicals. Employing artificial neural networks built on the ALGOPS software and ADMET forecaster, hundreds of substances' lipophilicity and solubility have been successfully predicted. Some DL techniques applied for the prediction of compound solubility are graph-based CVNNs and undirected graph recursive neural networks. In certain cases, algorithms were created to estimate the dissociation constant of acids for substances, such as ANN-based models, graphs kernels, and kernel ridge-based models. Similarly, cellular permeability data for a mixture of compounds were determined using cell lines, including human colon malignancy cells and Madin-Darby canine kidney cells, and then sent to artificial intelligencepowered professionals. Kumar et al. trained 745 compounds with Six models for estimation: SVMs, ANNs, knearest neighbor algorithms, LDAs, probabilistic neural network algorithms,



and partial least square (PLS), which they then used to estimate the gastrointestinal The absorption coefficient of 497 compounds was determined using molecular surface area, atomic mass, total hydrogen count, molecular refractivity, molecular volume, log P, total polar surface area, the sum of E-state indices, and the solubility index. In silico predictions of the gastrointestinal absorption of several substances were made using RF and DNN models. Indeed, The function of AI is critical. in drug development by anticipating the required bioactivity and physical and chemical properties. <sup>[9]</sup>

#### **5.2 Bioactivity Prediction**

The effectiveness of a drug molecule is determined by the affinity of the molecule to the targeted protein or receptor. Drug molecules can't produce a therapeutic response if they are not bound to the targeting protein or have an affinity for it. On the other hand, the generated medicinal compounds can sometimes Interact with unintended proteins or ligands and result in toxic effects. As a result, the DTBA is essential for predicting interactions between drugs and targets. Using traits or analogy between the medicine and its intended recipient, artificial intelligence-based methods can determine a drug's adherence

capacity. In order to identify specific feature vectors, feature-based approaches interaction determines the Chemical qualities of the medicine and the target. The distinction between the drug and the target has been taken into account in the instance of similarity-based interactions. That expectation states that similar medications interact with similar targets.

#### **5.3 Prediction of Toxicity**

To rule out unfavorable effects, the toxic potential of each drug candidate should be predicted. The conduct of animal trials to examine the toxicity of a candidate compound after its preliminary research based on frequent uses of cell-based in vitro assays increases the cost of drug development. However, there exist A number of web-based resources, such as Toxtree, admetSAR, pkCSM, and LimTox, to lower the cost. More sophisticated AI-based methods make use of input information to predict the toxicity of a compound or search for commonalities between compounds. An ML algorithm named DeepTox produced the best results; it was able to estimate a molecule's toxicity derived from predetermined 2500 toxicophore features by identifying both dynamic and static features in the molecules' chemically classifications, including weight of molecules and Van der Waals volume. In order to evaluate different computational techniques for estimating the toxicity of 12,707 environmental chemicals and medications, the US Food Drug Administration (FDA), the United States Environmental Protection Agency (EPA), and National Institutes of Health organized the Tox21 Data Challenge.<sup>[9]</sup>

### **5.4 Target Protein Structure Prediction**

For a medicinal molecule synthesized, the correct target should be chosen to ensure that it works as a treatment. The disease is caused by one type of protein and may occur in a variety of ways as a result of overexpression. It is consequently essential for estimating the morphology of a desired protein when creating a therapeutic chemical that preferentially targets disease. In this case, because the 3D protein structure is designed to meet the chemical background of the target protein site, AI can aid in structural-based drug development by identifying the potential compound action on the goal as well as risk factors prior to synthesis or manufacturing. To forecast the 3D targeted protein structure, the AI tool AlphaFold, which is based on DNNs, assessed distances between adjoining amino acid groups and related aspects of peptide bonding. It did excellent work, accurately forecasting 25 of 43 structures.<sup>[9]</sup>



A complex three-layered neural networks toolbox that depends on feedback supervising learning and the reverse propagation error approach using MATLAB was used to help predict the 2D protein structure. The MATLAB was fed both the input and outcome information sets, and the NNs served as learning algorithms and performance evaluaters. The 2D structure could be predicted with 62.72% accuracy. <sup>[9]</sup>

# 5.5 Identifying Interactions Between Drugs and Proteins

The interactions between drugs and proteins are crucial to the success of any treatment. Estimating what a medicine will do to a protein or receptor is a major question to answer in understanding a drug's efficiency and efficacy, and also facilitates repositioning the drugs of and avoids polypharmacology. Ligand- protein interaction predictions have been more accurate through various AI techniques in moving towards improved therapeutics. To identify nine emerging compounds and how they relate to four key targets, Wang et al. reported using a model trained on 15,000 protein-ligand interactions using the SVM technique. structural features and primary protein sequences from tiny compounds were used to create the model.<sup>[9]</sup>

# 6. Artificial Intelligence in Pharmaceutical Manufacturing

In response to the increasing complexity of production processes, as well as developing demand for efficiency and higher quality of products, modern manufacturing systems strive to imbue human knowledge in machines that can keep on changing the practices of manufacture. The pharmaceutical industry stands a chance of benefiting from manufacturing AI. Other tools and CFD utilise Reynolds-Averaged Application of the automation of many pharmaceutical processes, NavierStokes solvers technology is employed to investigate the influence of frustration and agitation levels in a variety of devices, including stirred tanks. Comparable technologies include numerical simulations that are performed directly and big eddy simulations, which use complicated resolve strategies to extremely complex disruptions flow in production. in The revolutionary Chemputer platform utilized a scripting language called Chemical Assembly and contains several chemical codes, which is highly based on the digital automation of synthesizing and manufacturing molecules. Sildenafil. diphenhydramine hydrochloride, and rufinamide have all been synthesized and manufactured with good success and vield and purity are astonishingly comparable with those from manual synthesis. AI technology can even accomplish homogenization in the granulators with capacities ranging from 25 to 600 liters. Their responses were connected to significant variables using technology and neuro-fuzzy logic. A polynomial equation was formulated by them for predicting the impeller diameter, the speed required, and the percentage of the granulation fluid which should be added in both Granulators that are geometrically similar and distinct. [9] For numerous investigations, including powder segregation in binary mixes, cutting edge rate and form impacts, tablet path predictions during coating, and tablet duration spent under the spray zone, DEM has been frequently used in the pharmaceutical sector. ANNs and fuzzy models analyzed the interdependence of settings of machines involved in the production line with the capping problem to decrease the capping of tablets in the production line.<sup>[9]</sup> Metaclassifier and tabletclassifier technologies are part of the wider context of artificial intelligence that may possibly regulate the final product's quality standard by pointing out possible manufacturing errors for tablets. A patent has been submitted showing a system of producing in a processor a best medication and dosage combination based on data received from the patient and then automatically producing the correct transdermal patch. <sup>[9]</sup>

# **7. Artificial Intelligence In Clinical Trial Design** Clinical trials are designed to establish whether a drug product is safe and effective for use in people to treat a given medical condition. However, these trials entail a period of about six to seven years with huge costs. This comes at a significant loss to the industry because, of every ten compounds that enter these trials, only one clears. In some cases, failures may result from poor infrastructural facilities, unmet technological needs, and occasionally inappropriately selected patients. However, the amount of digital medical data available makes all this possible through AI. <sup>[9]</sup>

This occupies one-third of the time in a clinical study. During the performance of clinical studies, there is a chance that only a percentage of registered patients could be Based on specific to the analyzing the patient's genome-exposome profile, AI may assist to Select which affected community to recruit for Clinical studies in phases II and III. The chosen patients' potential therapeutic targets may even be predicted early by this. the intended afflicted group, as failure cases make up roughly 86% of all trials. Preliminary predictions of the key compounds that will survive clinical trials are also aided by preclinical molecule discovery and earlier lead compound prediction prior to the start of clinical trials, taking into account the selected group of patients and other predetermined features of artificial intelligence. [9] Because of dropout cases of the patients, thirty percent of clinical trails fail in the completion process, wasting time and moneyThis is avoided by regularly keeping monitoring on the patients and helping them follow the approved clinical study process. During a Phase II study, Ai Cure developed portable applications that monitored the regular prescription drug use of schizophrenic patients. This raised patient

compliance by 25%. It was indispensable for the successful conduct of a clinical trial. <sup>[9]</sup>

# 8. Artificial Intelligence In Quality Control And Quality Assurance

Here, a mixture of several factors must be adjusted to obtain the desired product out of raw materials. The intervention is manual for achieving consistency from batch to batch and carrying out the quality control tests on the products. It is not the optimal solution in all cases, which showcases why AI needs to be implemented at this juncture. The FDA embraced a "Quality by Design" approach to the Current Good Manufacturing Practices in order acquire a deeper understanding of the critical steps a specific requirements that define quality at release. [9] Gams et al. derived decision trees from preconditioned data emanating from batches of production through a mix of human efforts and artificial intelligence. The operators assessed them and turned their interpretations into guidelines that would now control the manufacturing cycle. Goh et al. used artificial neural networks (ANN) to estimation of the dissolution of a tested production with a variance of less than 8% and examine the dissolution profile of a measure of theophylline pellets' batch-to-batch consistency. <sup>[9]</sup> To reach the required level of product quality, artificial intelligence is also beneficial for controlling inline production procedures. The method of freezing and drying is monitored using artificial neural networks (ANNs), which comprise backpropagation, local search, and self-adaptive evolution approaches. This can eventually help to maintain control over the quality of the finished product by predicting the temperature and desiccated-cake thickness at a future time point (t + Dt) for a specific set of operational specifications. <sup>[9]</sup> Quality assurance of the product can be ensured through the use of advanced, subtle techniques in conjunction with an automated platform for data input, in this case, an Electronic



Lab Notebook. The data mining tool included in the TQM expert system, as well as other knowledge discovery tools, will assist in making tough decisions and developing novel innovations for intelligent quality monitoring.<sup>[9]</sup>

# 9. Benefits And Risks Of Using Artificial Intelligence For Pharmaceutical Development And Delivery

### 9.1 Determining and Optimizing AI's Benefits for Public Health in the Production and Distribution of Pharmaceuticals

AI can have greater advantages to global and health of the public. This will require a conscious direction of AI towards harnessing the yet unexploited pockets of medicinal development or access within the present pharmaceutical system, as well as in meeting unmet needs. It would also call for proactive measures from governments, foundations, and NGOs as supportive investments, laws, and practices. Here are some possible applications. <sup>[3]</sup>

# 9.1.1 Medicines and Vaccines to Address Unmet Needs

AI has the potential to manufacture vaccines and drugs not currently manufactured in pharmaceutical R&D. So far, investments have been made on three focus areas: vaccinations against pandemic risks, neglected tropical illnesses, and antibiotic resistance. <sup>[3]</sup>

The researchers have the abilities to estimate a target disease's protein configurations. because AlphaFold2's structure had been developed in collaboration with DeepMind and the Drugs for Rare Diseases Initiative, a charitable organization dedicated to creating new medications opposing overlooking tropical diseases and other transmissible conditions such as hepatitis C and COVID-19. With this in mind, the collaboration targeted this protein to determine if the experimental substance being developed by drugs for neglected diseases initiative can bind to the protein of the parasite Trypanosoma cruzi, which

causes Chagas disease, and can kill the parasite. This could also suggest other compounds that may be able to attach to the protein. To tap into previously undiscovered targets for antibacterial drug discovery, DeepMind teamed up with the Global Antibiotic Research and Development Partnership, a non-profit organization that innovates treatments for drug-resistant diseases.<sup>[3]</sup>

# 9.1.2 Making Clinical Trials more Inclusive

As a result, such studies may involve 86% of White participants only, whereas 79% of genetic information currently available comes from individuals of European ancestry. The sex and gender bias in R&D is also well reflected in the fact that clinical trials do not admit those of childbearing age or pregnant and nursing women, such as 73. Increasing diversity in clinical trials will be challenging; initiatives include the use of incentives, regulatory drivers, and partnerships with non- profit and other organizations. Some examples include the 2022 USA legislation that requires "diversity action plans" for any clinical trials assessed by the US Food and Drug Administration for safety and efficacy with medications. In order to fulfill the necessities of the main population groups that the interference is meant to benefit-with special concern for underrepresented populations—the Director General is anticipated to offer informal direction on guidelines for outside actors in the planning and execution of clinical trials as well as in bolstering the global clinical trial ecosystem. In 2022, WHO Member States accepted this resolution with the intention of bolstering clinical studies. Discussion with the States Parties and pertinent non-state entities was necessary in order to formulate this resolution.<sup>[3]</sup>

#### 9.1.3 Strengthening Pharmacovigilance

The detection of safety signals—information that would indicate potentially adverse events resulting from the intake of a pharmaceutical drug—is an area where artificial intelligence could assist, both



in the course of a clinical trial and later when a gained regulatory medication has already approval. However, given the increase in adverse reaction reports, this type of AI capability can Recognize security warnings that are extremely challenging to detect using modern techniques, such as diseases that interact with drugs, interactions among drugs, errors in medication, secondary carcinomas. variations in the occurrence and severity of recognized activities, and structures of medication utilize and abuse. The artificial intelligence (AI) can be utilized to detect undesirable events to determine whether a case report is valid and meets the minimal reporting standards. The detection of safety signalsinformation that would indicate potentially adverse events resulting from the intake of a pharmaceutical drug-is an area where artificial intelligence could assist, both in the course of a clinical trial and later when a medication has already gained regulatory approval. However, given the increase in adverse reaction reports, this type of AI capability will recognize security indicators that are extremely complicated to detect Using modern strategies, such as drug-disease interactions, interaction between drugs, errors in medication, secondary carcinomas, variations in the prevalence and seriousness of recognized activities, and patterns of drug consumption and abuse. The AI can be utilized to detect undesirable events to determine whether a case report is valid and meets the minimal reporting standards. The Peek Platform is monitoring technology developed by WHO that relies on AI to identify, classify, and detect information about COVID-19 vaccination side effects found in online forums.<sup>[3]</sup>

# 9.1.4 Monitor the Purchasing, Distribution, and Supply of Medications in Low- and Middle-Income Nations

Regarding the distribution and supply of pharmaceuticals and vaccines, which are mostly found in countries with low to middle incomes, there are two interconnected problems: drug shortages and out-of-stock and a lack of supply chain transparency. The aim of universal health coverage is hampered by this. Significant expenditures will be required to bridge the digital divide and guarantee that the correct data is collected, even though pharmaceutical companies are now more than ever depending on AI to manage the supply and distribution of medicines, 57 including the monitoring of the refrigeration chain for vaccine transportation, 58 in countries with low to middle incomes. Such sectors are thus most likely the ones that have encounters of stockouts and shortage within a country's health system because they are also more unlikely to have connectivity to collect the data required.<sup>[3]</sup>

#### 9.2 Risks and Challenges

AI technologies present challenges and barriers besides benefits to drug development and public health. The WHO's guidance on morality and governance of artificial intelligence for healthcare detects ten distinct problems with its application. These issues pertain to the application of AI in pharmaceuticals production.<sup>[3]</sup>

### 9.2.1 Bias

Bias, as discussed above, is already creeping into the design of drugs and vaccines. With regards to race, ethnicity, gender, age, etc., clinical testing of experimental agents for such agents often

leaves out some of these diverse patient populations. That can make it tougher to obtain universal health care coverage. For instance, it typically takes ten years to gain access to pediatric formulations of adult antibiotics and infectious diseases medications like HIV/AIDS. <sup>(3)</sup> Many applications of AI in the health sector are often perpetuated by biases and discrimination. The three major kinds of bias include datasets for AI training , people-related to those creating them, and related to the implementation of the technology-contextual bias. <sup>[3]</sup>

9.2.2 Safety



Thus, if Pharmaceutical production algorithms are not screened Any prospective issues or if they generate, for example, false positives or false negatives, then patient safety is at risk. Within less than six hours, an algorithm has been shown to be able to identify 40,000 harmful Chemical ingredients that potentially may be employed as biological instruments. besides identifying or constructing new, medicinally useful molecules. Therefore, as the researcher said, "AI can be dangerous if let loose on the world of biology." Although this type of research can be carried out by human beings without AI, this type of fear gets amped up by the fast and precise spread of such technology. WHO has released guidelines to guide dual use research after it has identified the issue as a major area related to bio-risk. The above governments have to introduce rules and regulations to prevent such threats.<sup>[3]</sup>

#### 9.2.3 Transparency and Explanation

As with other applications of Artificial intelligence (AI) in healthcare and medical research, when decisions are reached through "black-box" algorithms, scientists, regulators, and healthcare workers might have to grapple with ethical questions when relying on AI to synthesize new drugs. Many algorithms that employ Artificial neural networks and other complicated algorithms are often considered "black boxes," meaning they are making decisions and drawing conclusions that even their designers do not really comprehend (1). Then, there can be a trade-off between the precision and efficacy of an algorithm (at the expense of comprehensibility) and its perfect "explainability" (at the expense of accuracy and effectiveness). To ensure that all algorithms meet effectiveness safety and criteria. WHO recommends their adequate testing in the environments in which the technology will be used. The following should be assessed: assumptions regarding the AI technology, operating procedures, characteristics of data, and

output choice. Provided that a relevant regulatory body can be persuaded by a developer that interpretable models demonstrate "unsatisfactory performance or robustness," black box algorithms with certain positions can be accepted. <sup>[3]</sup>

#### 9.2.4 Responsibility and Accountability

Being responsible assures that the Residents and organizations responsible for the immoral action will be able to be held accountable in case of any adverse consequences of their actions. Beyond that, trust and protection of human rights require responsibility. This may be established first of all by preventing or minimizing damage or harm. <sup>[3]</sup>

Those characteristics of AI technologies - its opaqueness, dependence on human involvement, discretion, involvement, Flexibility, ability to provide details, and software complexity - do influence ideas of responsibility (and accountability). A single obstacle of apportioning reliability. is the "control problem," which asserts that AI designers and developers cannot be held responsible because AI- guided systems are said to operate independently of them and may adjust in ways that their developers are able to make assertions were unforeseeable. Instead, there remains a responsibility gap. At any point in the development process, employing AI that doesn't work as intended would put undue pressure on the person who is harmed. They have no control over the situation, and Designers and developers have been unable to held accountable since they are the only ones who can be blamed, but they may still be held accountable. <sup>[3]</sup>

#### 9.2.5 Privacy and Informed Consent

Health and other data must be gathered, evaluated, and used at every stage of the AI application process for medication research, development, and post-marketing industrialization. As a result, when making investments in AI medications, the IT and pharmaceutical sectors both Utilize information that they ultimately possess, such as the vast volumes of clinical trial data that the

Pharmaceutical firms have. Most of these businesses even attain more patient data from social media and other sources including hospital systems, which include genetic and cellular data. <sup>[3]</sup> The possible benefits of biological "big data" and health information may be morally essential because they have the potential for new drug discovery of previously unknown targets, potentially accelerating the speed and improving the accuracy of phase II and III clinical trials, and reducing the rates of attrition. However, using health data in AI-informed medicine creates a significant number of problems specifically on protection as regards everybody's right to privacy. Where a deprivation of privacy may injure some individual, say, to discrimination, manipulation or exploitation based on health status, it may also be the source of enablement of wrongdoing-for instance, of the individual's security, liberty, or integrity were confidential Healthcare data disclosed or displayed. This is the reason why the gathering, use, analysis, and public disclosure of health information have always been controversial issues relating to individual privacy. Sharing or exchanging data might expose consumers to government exploitation, cyber-theft. unintentional disclosure, unfair health insurance terms, or deceptive marketing tactics.<sup>[3]</sup>

### CONCLUSION

Drug discovery will be much better integrated with AI and automation in the future. In the best case, AI will be able to make direct decisions about which compounds to synthesize and design without requiring the intervention of a human. It should theoretically be possible to expedite drug discovery and offer improved beginning points for drug development if the transition from an upgraded to an autonomous drug design methodology is made possible. The aim is to achieve fully self-sustaining labs that can manage development cycle the drug of design, manufacture, test, and analyze independently. This

should lead to more streamlined and quicker procedures for AI systems to suggest and test new compounds without human intervention. However, some challenges still need to be the resolved: ensuring consistency and reproducibility of results based on AI. Additionally, for the successful introducing AI into future Investigation of drugs, substantial investment in AI technology and access to strong datasets is required. In the development process of a novel medicament, there are two primary challenges that the pharmaceutical industry faces: cost overrun and lower productivity efficiency. There are multiple opportunities using ML techniques and new DL advances to reduce the cost, boost productivity, and reduce time spent During the process of discovering and developing new drugs. Though, for now, there is still much that needs to be done and quite many obstacles on the way to finally introduce AI tools into the drug discovery cycle, in action, AI already succeeded in promising results with regard to new material combinations for the purpose of discovering new drugs. AI accelerates the Research potential medications, increases target identification, optimizes formulation and drug delivery, and improves virtual screening. With such advances on the horizon in automated decision-making and the merging of Artificial intelligence and automation, the future looks indeed bright for AI within drug discovery.<sup>[15]</sup>

#### REFERENCES

- Noorain, Srivastava, V., Parveen, B., & Parveen, R. (2023). Artificial intelligence in drug formulation and development: applications and future prospects. Current drug metabolism, 24(9), 622-634.
- Jiang, J., Ma, X., Ouyang, D., & Williams III, R. O. (2022). Emerging artificial intelligence (AI) technologies used in the development of solid dosage forms. Pharmaceutics, 14(11), 2257.



- 3. World Health Organization. (2024). Benefits and risks of using artificial intelligence for pharmaceutical development and delivery. World Health Organization.
- Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: a review. The AAPS journal, 24, 1-10
- Rights are reserved by Sakshi, A., & Dashpute,
  V. Artificial Intelligence and Machine Learning in the Pharmaceutical Industry.
- Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics, 16(10), 1328.
- Raparthi, M., Gayam, S. R., Nimmagadda, V. S. P., Sahu, M. K., Putha, S., Pattyam, S. P., ... & Kuna, S. S. (2022). AI Assisted Drug Discovery: Emphasizing Its Role in Accelerating Precision Medicine Initiatives and Improving Treatment Outcomes. HumanComputer Interaction Perspectives, 2(2), 1-10
- Ali, K. A., Mohin, S. K., Mondal, P., Goswami, S., Ghosh, S., & Choudhuri, S. (2024). Influence of artificial intelligence in modern pharmaceutical formulation and drug development. Future Journal of Pharmaceutical Sciences, 10(1), 53.
- Mak, K. K., Wong, Y. H., & Pichika, M. R. (2023). Artificial intelligence in drug discovery and development. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays, 1- 38.
- Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: present status and future prospects. Drug discovery today, 24(3), 773-780.

- Sable, P., & Khanvilkar, V. V. (2018). Pharmaceutical applications of artificial intelligence. Int. Pharma. Res. Health Sci, 6, 2342-2345.
- Sultana, A., Maseera, R., Rahamanulla, A., & Misiriya, A. (2023). Emerging of artificial intelligence and technology in pharmaceuticals. Future Journal of Pharmaceutical Sciences, 9(1), 65.
- 13. Damiati, S. A. (2020). Digital pharmaceutical sciences. AAPS PharmSciTech, 21(6), 206.
- Gertrudes, J. C., Maltarollo, V. G., Silva, R. A., Oliveira, P. R., Honorio, K. M., & Da Silva, B. F. (2012). Machine learning techniques and drug design. Current medicinal chemistry, 19(25), 4289-4297.
- 15. Visan, A. I., & Negut, I. (2024). Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life, 14(2),23

HOW TO CITE: Shruti Kapadne\*, Tejaswini Khairnar, Rutika Karad, Sakshi Kawale, Pankaj Aher, Artificial Intelligence in Pharmaceutical Production, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 260-275. https://doi.org/10.5281/zenodo.14802836

